Alpha IVF Group posted a net profit attributable to shareholders (PATMI) of RM38.9 million on group revenue of RM120.8 million for the nine months ended 29 February 2024 (9M24). There is no comparison to the corresponding period of the previous year, as it was listed on the ACE market of Bursa Malaysia Securities Berhad on 22 March 2024, after the closing of 9M24.
In the previous financial year ended 31 May 2023 (FYE 2023), the Group recorded RM137.5 million revenue and RM53.2 million PATMI. The PATMI in FYE 2023 included a fair value gain of RM11.3 million, without which the Group’s core PATMI would have been RM41.9 million. The 9M24 financial performance saw the group revenue and PATMI already achieving 87.9% and 92.8% of those of FYE 2023 respectively. The percentages are a pointer to an outperformance year in FYE 2024, as demand for In-vitro Fertilisation (IVF) treatments continues to rise, driven by the rising number of overseas patients seeking treatment in Malaysia, along with expanding domestic demand.
In 9M24, Malaysia’s operations made up 80.7% or RM97.5 million of overall group revenue, with the rest coming from Singapore’s operation. Of the revenue from Malaysian operations, 58.2% were attributed to foreign patients from Indonesia, China and Singapore, versus only 50.9% in the full year of FYE 2023.
For the third quarter ended 29 February 2024 (3Q24), group revenue stood at RM40.7 million, with a PATMI of RM13.6 million. As this is the Group’s first financial report on consolidated results after the listing on the ACE market, there is no comparison to the corresponding period of the previous year.
